WEKO3
アイテム
{"_buckets": {"deposit": "7c1fc644-eab4-4a3e-98ed-cc9810d009a3"}, "_deposit": {"created_by": 1, "id": "49141", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "49141"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00049141", "sets": ["1"]}, "author_link": ["495784", "495777", "495778", "495770", "495771", "495767", "495776", "495782", "495768", "495773", "495775", "495779", "495780", "495766", "495783", "495769", "495781", "495772", "495774"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "6", "bibliographicPageEnd": "1010", "bibliographicPageStart": "999", "bibliographicVolumeNumber": "45", "bibliographic_titles": [{"bibliographic_title": "European Journal of Nuclear Medicine and Molecular Imaging"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Purpose: Therapeutic options for patients with malignant pheochromocytoma are currently limited, and therefore new treatment approaches are being sought. Targeted radionuclide therapy provides tumor-specific systemic treatments. β-emitting radiopharmaceutical meta-131I-iodo-benzylguanidine (131I-MIBG) has limited survival benefits and adverse effects. A new generation of radionuclide therapy using α-particles including meta-211At-astatobenzylguanidine (211At-MABG) is expected to have strong therapeutic effects with minimal side effects. However, this possibility has not been evaluated in a pheochromocytoma animal model. We aimed to evaluate the therapeutic effects of α-emitter 211At-MABG on a pheochromocytoma model. \nMethods: We evaluated tumor volume-reduction effects of 211At-MABG using rat pheochromocytoma cell line PC12 tumor-bearing mice. PC12 tumor-bearing mice received 211At-MABG (0.28, 0.56, 1.11, 1.85, 3.70 and 5.55 MBq; n = 5 each group) intravenously. The tumor volume was evaluated until 8 weeks after 211At-MABG administration. Control group (n = 10) received phosphate buffered saline (PBS).\nResults: The single 211At-MABG therapy showed significantly lower relative tumor growth until 38 days compared to control [relative tumor volume, control: 509.2% ± 169.1% vs. 9.6% ± 5.5% (0.56 MBq) at day 21, p \u003c 0.01]. In addition, the 211At-MABG treatment groups with 0.28, 0.56 and 1.11 MBq showed only temporary weight reduction, recovering weight loss at day 10.\nConclusion: 211At-MABG exhibited a strong tumor volume-reduction effect in a pheochromocytoma mouse model without weight reduction. Therefore, 211At-MABG might be an effective therapeutic agent for the treatment of malignant pheochromocytoma.", "subitem_description_type": "Abstract"}]}, "item_8_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer International Publishing AG"}]}, "item_8_relation_13": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "29350258", "subitem_relation_type_select": "PMID"}}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1007/s00259-017-3919-6", "subitem_relation_type_select": "DOI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1619-7070", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "大島, 康宏"}], "nameIdentifiers": [{"nameIdentifier": "495766", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "須藤, 仁美"}], "nameIdentifiers": [{"nameIdentifier": "495767", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "渡辺, 茂樹"}], "nameIdentifiers": [{"nameIdentifier": "495768", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "永津, 弘太郎"}], "nameIdentifiers": [{"nameIdentifier": "495769", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻, 厚至"}], "nameIdentifiers": [{"nameIdentifier": "495770", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "坂下, 哲哉"}], "nameIdentifiers": [{"nameIdentifier": "495771", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "伊藤, 陽一"}], "nameIdentifiers": [{"nameIdentifier": "495772", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "吉永, 恵一郎"}], "nameIdentifiers": [{"nameIdentifier": "495773", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "東, 達也"}], "nameIdentifiers": [{"nameIdentifier": "495774", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "石岡, 典子"}], "nameIdentifiers": [{"nameIdentifier": "495775", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "大島 康宏", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "495776", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "須藤 仁美", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "495777", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "渡辺 茂樹", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "495778", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "永津 弘太郎", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "495779", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻 厚至", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "495780", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "坂下 哲哉", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "495781", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "吉永 恵一郎", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "495782", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "東 達也", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "495783", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "石岡 典子", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "495784", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/49141", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-08-16"}, "publish_date": "2018-08-16", "publish_status": "0", "recid": "49141", "relation": {}, "relation_version_is_last": true, "title": ["Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model"], "weko_shared_id": -1}
Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model
https://repo.qst.go.jp/records/49141
https://repo.qst.go.jp/records/4914128d4bd11-c7e1-4def-8e08-35a9082a87e3
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-08-16 | |||||
タイトル | ||||||
タイトル | Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
大島, 康宏
× 大島, 康宏× 須藤, 仁美× 渡辺, 茂樹× 永津, 弘太郎× 辻, 厚至× 坂下, 哲哉× 伊藤, 陽一× 吉永, 恵一郎× 東, 達也× 石岡, 典子× 大島 康宏× 須藤 仁美× 渡辺 茂樹× 永津 弘太郎× 辻 厚至× 坂下 哲哉× 吉永 恵一郎× 東 達也× 石岡 典子 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Purpose: Therapeutic options for patients with malignant pheochromocytoma are currently limited, and therefore new treatment approaches are being sought. Targeted radionuclide therapy provides tumor-specific systemic treatments. β-emitting radiopharmaceutical meta-131I-iodo-benzylguanidine (131I-MIBG) has limited survival benefits and adverse effects. A new generation of radionuclide therapy using α-particles including meta-211At-astatobenzylguanidine (211At-MABG) is expected to have strong therapeutic effects with minimal side effects. However, this possibility has not been evaluated in a pheochromocytoma animal model. We aimed to evaluate the therapeutic effects of α-emitter 211At-MABG on a pheochromocytoma model. Methods: We evaluated tumor volume-reduction effects of 211At-MABG using rat pheochromocytoma cell line PC12 tumor-bearing mice. PC12 tumor-bearing mice received 211At-MABG (0.28, 0.56, 1.11, 1.85, 3.70 and 5.55 MBq; n = 5 each group) intravenously. The tumor volume was evaluated until 8 weeks after 211At-MABG administration. Control group (n = 10) received phosphate buffered saline (PBS). Results: The single 211At-MABG therapy showed significantly lower relative tumor growth until 38 days compared to control [relative tumor volume, control: 509.2% ± 169.1% vs. 9.6% ± 5.5% (0.56 MBq) at day 21, p < 0.01]. In addition, the 211At-MABG treatment groups with 0.28, 0.56 and 1.11 MBq showed only temporary weight reduction, recovering weight loss at day 10. Conclusion: 211At-MABG exhibited a strong tumor volume-reduction effect in a pheochromocytoma mouse model without weight reduction. Therefore, 211At-MABG might be an effective therapeutic agent for the treatment of malignant pheochromocytoma. |
|||||
書誌情報 |
European Journal of Nuclear Medicine and Molecular Imaging 巻 45, 号 6, p. 999-1010, 発行日 2018-01 |
|||||
出版者 | ||||||
出版者 | Springer International Publishing AG | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1619-7070 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 29350258 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1007/s00259-017-3919-6 |